Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol).
Antral biopsies were obtained to detect Campylobacter pylori infection in 382 patients referred for gastroscopy. One hundred and seventy four patients (46%) were infected. Infection was strongly associated with histological gastritis (p less than 0.001), but there was no association between histological antral gastritis and the appearance of the gastric antrum during gastroscopy. Because it has been suggested that the lower relapse rate for duodenal ulcer following colloidal bismuth subcitrate (CBS) is due to suppression of C pylori we investigated different formulations and dosing of CBS for their efficacy in clearing C pylori. Seventy four infected patients were prospectively assigned to therapy with pirenzepine (11 patients) or one of four regimens of CBS; one swallow tablet 4 times a day (11 patients); two swallow tablets twice daily (16 patients); two buffered swallow tablets twice daily (14 patients); or two chew tablets twice daily (22 patients). All patients treated with pirenzepine and one CBS swallow tablet 4 times a day were still infected after treatment. Infection was not detected in 16 patients taking twice daily doses of CBS; 8 (50%), 3 (21%) and 5 (23%) patients taking two standard, buffered or chew tabs twice daily respectively. Improvement of histological gastritis was observed only in those patients apparently cleared of C pylori (p less than 0.01) and this was due to a decrease in polymorphonuclear leukocytes. Nine patients apparently cleared of the infection were rebiopsied 44-137 days following treatment and 6 (66%) were found again to be infected. This study suggests that suppression of C pylori may vary with the formulation and dosing of CBS.(ABSTRACT TRUNCATED AT 250 WORDS)
Morris
A
A
Department of Microbiology, Middlemore Hospital, Otahuhu, Auckland.
Brown
P
P
Ali
M R
MR
Lane
M
M
Palmer
R
R
D000284:Administration, Oral; D000328:Adult; D001706:Biopsy; D001729:Bismuth / Q000008:administration & dosage / Q000627:therapeutic use*; D002167:Campylobacter / Q000302:isolation & purification; D002169:Campylobacter Infections; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D010890:Pirenzepine / Q000008:administration & dosage / Q000627:therapeutic use*; D011706:Pyloric Antrum / Q000382:microbiology / Q000473:pathology; D011897:Random Allocation; D012008:Recurrence
D009942:Organometallic Compounds; D010890:Pirenzepine; C002791:bismuth tripotassium dicitrate; D001729:Bismuth